Immunotech A.S. Issues Recall for Estrone RIA Kits Over Inaccurate Test Results
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Immunotech A.S. is recalling 160 Estrone RIA kits due to a defect that may cause falsely high patient results, posing a risk of temporary injury.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references Worldwide. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, medical-device.
What Happened
Immunotech A.S. has initiated a voluntary recall of specific lots of its Estrone RIA diagnostic kits. The recall was prompted by the discovery that affected kits may rarely produce falsely high patient results. According to the company, while the probability of occurrence is remote, these inaccuracies could potentially lead to temporary injury for patients.
Which Products Are Affected
The recall impacts the following medical device:
- Product Name: Estrone RIA
- Reference Number: DSL8700
- UDI: 15099590211615
- Affected Lots (Expiration Dates): 251013C (2025-12-30) and 251110C (2026-01-27)
- Quantity: 160 units
Distribution of these units is worldwide, including nationwide distribution within the United States (specifically North Carolina), as well as Germany, Argentina, Netherlands, Hungary, Austria, Belgium, France, and Italy.
What You Should Do
The firm initiated the recall process by sending notification letters to affected customers. Laboratories and healthcare providers should immediately check their inventory for the specified lot numbers and follow the instructions provided in the firm's notification letter regarding the handling or return of the affected kits.
Why This Matters
Reliable diagnostic results are essential for proper patient management. Falsely elevated estrone levels could lead to misdiagnosis or inappropriate clinical interventions, though the risk of serious harm is considered low and the probability of the defect occurring is remote.
Source
Information provided by the FDA under recall number Z-1369-2026.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.